New approaches targeting dry eye subtypes

In Part 1 of Insight’s dry eye series, Dr Laura Downie explains how an explosion in global investment in dry eye research and development is paving the way for a range of new therapies, particularly those more specifically aimed at dry eye subtypes. Read more

Dry eye treatment in Australia

Dry eye remains a very common presentation to primary eyecare practitioners in Australia. Many experienced practitioners feel that the incidence of dry eye is increasing significantly. This is a complex and multifactorial disease which begs the question: Are we doing enough for our patients and how could we do better? Read more

Opthea becomes ASX top 300 company

Melbourne biopharmaceutical company Opthea has announced its inclusion on the ASX 300, just days after its lead drug candidate met primary end points in the latest clinical trial for diabetic macular edema (DME). Read more

Novartis provides safety update for Beovu

A safety review into Novartis’ new anti-VEGF drug Beovu has revealed that reported adverse events are consistent with the approved prescribing information after a group of US retinal specialists linked it to a series of vasculitis cases. Read more